Heart Attack Clinical Trials 2023

What are the top hospitals conducting heart attack research?

When it comes to cutting-edge clinical trials in the field of heart attack treatment, several hospitals have emerged as pioneers. In Rochester, Minnesota, the Mayo Clinic takes a leading role with four ongoing heart attack trials and a commendable history of six previous studies dedicated to this condition. This prestigious institution has been at the forefront of cardiovascular research since conducting its first trial in 2013. Similarly, Duke University Medical Center in Durham, North carolina, has also made significant contributions with four active heart attack trials and an impressive track record of twelve completed studies dating back to their earliest recorded trial in 2000.

The University of Pittsburgh Medical Center (UPMC) is another notable contender on this list. Located in Pittsburgh, Pennsylvania, UPMC currently conducts four active clinical trials for heart attacks and has conducted seventeen such trials over the years since initiating its inaugural study on this topic in 2006. Meanwhile,Vancouver General Hospital situated in Vancouver joins UPMC with an equivalent number of both ongoing and previously conducted cardiac arrest experiments - specifically fourendeavors each from their starting point back until 2003.

Additionally making itself known is Reid Physician Associates based out Richmond where they are overseeing three ongoing investigative projects aboutheart attacks while having successfully concluded three similar past ones followingtheir initial endeavor which took place just last year during2020.

These esteemed institutions demonstrate not only dedication but immense progress when it comes to understanding and treating heart attacks. By engaging patients in groundbreaking clinical trials, these hospitals pave the way for innovative treatments that can potentially save countless lives worldwide

Which are the best cities for heart attack clinical trials?

When it comes to heart attack clinical trials, several cities stand out as leaders in research and development. New york, New York leads the pack with 14 active trials exploring treatments like Liberal Transfusion Strategy, Enhanced Usual Care (EUC), and Orbital Atherectomy (OA). Edmonton, Alberta follows closely behind with 11 ongoing studies focused on interventions such as Liberal Transfusion Strategy and Implantable Cardioverter Defibrillator + Usual Care. Pittsburgh, Pennsylvania also contributes significantly to research efforts with 10 active trials investigating topics including Blood Transfusion and In-person cardiac rehabilitation. These cities offer individuals affected by heart attacks access to cutting-edge clinical trials that hold promise for improved outcomes and advancements in care.

Which are the top treatments for heart attack being explored in clinical trials?

Exciting advancements are underway in clinical trials for heart attack treatments. Leading the charge is intervention, a proven approach currently being explored in two active trials and one all-time trial since 2005. Another promising contender is the Ellipsis Health Voice Application, making waves with its innovative technology. It is undergoing testing in one active trial and has already shown promise as a potential treatment option since its first listing in 2022. These groundbreaking developments offer hope for improved outcomes and recovery for individuals who have experienced a heart attack.

What are the most recent clinical trials for heart attack?

Exciting advancements are being made in the field of heart attack research, with recent clinical trials shedding light on potential breakthrough treatments. One such trial is GXT+ THHR, an intervention that shows promise in improving outcomes for individuals who have suffered a heart attack. Additionally, Inclisiran Sodium 300mg has entered Phase 3 testing and holds great potential as a treatment option for heart attack patients. Another noteworthy study focuses on Deferiprone's effectiveness in treating hemorrhagic myocardial infarction—a crucial step forward towards enhancing patient care during this critical condition. Lastly, Evolocumab + Routine Lipid Management is undergoing Phase 4 trials to evaluate its efficacy in reducing recurrent heart attacks. These groundbreaking studies offer hope and pave the way for better care and improved outcomes for those affected by heart attacks.

What heart attack clinical trials were recently completed?

Recently completed clinical trials in the field of heart attack have provided valuable insights into potential treatment options. In December 2020, R-Pharm Overseas, Inc. concluded a trial investigating the efficacy of RPH-104 80 mg in managing heart attacks. Furthermore, the University of Arkansas completed a trial involving Aspirin 81 mg in November 2018, while the University of Maryland, Baltimore wrapped up their study on Clopidogrel in August 2017. These significant findings contribute to our understanding and management strategies for this life-threatening condition.